Last reviewed · How we verify

PTC Therapeutics — Portfolio Competitive Intelligence Brief

PTC Therapeutics pipeline: 0 marketed, 0 filed, 2 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 3 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ataluren (PTC124®) Ataluren (PTC124®) phase 3 Nonsense suppression agent Ribosome (eukaryotic translation machinery) Rare genetic diseases
PTC923 PTC923 phase 3 Pyruvate dehydrogenase kinase (PDK) inhibitor PDK (pyruvate dehydrogenase kinase) Rare genetic/metabolic disorders

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. National Health Research Institutes, Taiwan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PTC Therapeutics:

Cite this brief

Drug Landscape (2026). PTC Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ptc-therapeutics. Accessed 2026-06-10.

Related